Navigation Links
Smartphone Technology Meets Personalized Medicine in Everist Genomics' CardioDefender Diagnostic System
Date:1/27/2012

ve monitoring needed to detect potentially life threatening arrhythmias," Charlton said. "For the first time, CardioDefender enables smartphone-based hospital-quality ECG monitoring of patients 24 hours per day, seven days per week."

The company's recently announced commercialization plans of CardioDefender coincide with reports from various industry sources projecting significant growth in remote patient monitoring.  According to analyst firm Berg Insight, for example, around 2.2 million patients worldwide were using home monitoring service based on equipment with integrated connectivity at the end of 2011—cardiac arrhythmia was cited as one of the most common conditions monitored by these technologies.(1)

Following FDA approval and European CE Mark registration last year, CardioDefender has already been deployed at more than 150 medical facilities in the United States for post-approval commercial evaluation.  Between January and October of 2011, the number of patient days of heart rhythm monitoring performed with CardioDefender grew from fewer than 5,000 to more than 18,000 patient days per month. Since the system was introduced, Everist Genomics has received inquiries about the product from more than 32 countries, including China, India and the U.S.

"We are very pleased with the success of the commercial evaluation of CardioDefender and the overwhelming level of interest we have received regarding the availability of the diagnostic system," Charlton said. "The invitation to speak at the highly-esteemed Wearable Technologies Conference further underscores the value of this innovative mobile system in advancing care for arrhythmia patients."

Everist Genomics launched its first product last year with the introduction of OncoDefender-CRC, a prognostic test for predicting the risk of disease recurrence for early stage colorectal cancer patients. The company expanded its pipeline with the creation of a new franchise of diag
'/>"/>

SOURCE Everist Genomics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. New Web Technology Now Allows for Pharmaceutical Reps to Receive Training on Their Desktops, Tablets, and Smartphones
2. UBM TechInsights Issues Warning to Medical Devices Industry About Possible Obsolescence as Reliance on Smartphones Increases
3. New Smartphone App Launches for Cardiac Imaging Test
4. Good Medicine: Smarter Smartphones for People With Chronic Disease
5. Aria Announces Publication of Independent Study in the American Journal of Obstetrics & Gynecology Using Arias Technology
6. Soligenix Receives $574,000 in Non-Dilutive Financing from New Jerseys Technology Business Tax Certificate Transfer Program
7. Heart Hospital of Austin Opens Heart Valve Clinic, Among First Sites in U.S. to Receive New Trans-Catheter Aortic Valve Replacement Technology Since FDA Approval
8. Oramed Pharmaceuticals Granted Australian Patent for Important Part of the Companys Core Technology in Oral Delivery of Proteins
9. Arizona Heart: Three Advanced Technology Operating Rooms With State-of-the Art C-arm Solutions
10. WestPark Capital, Inc. Announces $500,000 Arrogene NanoTechnology, Inc. Offering
11. Zyga Technology, Inc. Makes Two Key Additions to the Sales Leadership Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Mass. , Jan. 15, 2014  Zafgen, Inc., ... unmet needs of severely obese patients, today announced ... beloranib, a selective inhibitor of methionine aminopeptidase 2 ... severe form of genetic obesity.  These results showed ...
(Date:1/14/2014)... Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... results for the fourth quarter of 2013 on Monday, February ... for release after the close of trading. ... conference call to discuss the operating highlights and financial results ...
(Date:1/14/2014)... Dynamic Healthcare Services, Inc. ("DHS"), a portfolio company of GMH ... Medical Equipment, Inc. ("Progressive") of Clarion, PA ... were not disclosed. Progressive is a full ... of sleep, mobility, and respiratory products to customers in the ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... BRISBANE, Calif., Oct. 27, 2011 InterMune, Inc. (NASDAQ: ... third quarter 2011 financial results at the close of the ... call and webcast will be hosted by InterMune at 4:30 ... and others may participate in the conference call by dialing ...
... 2011 Total quarterly revenues of ... grow 17 Percent, reflecting strong performance of OPANA® ER, Voltaren® Gel ... of $0.34 versus $0.46 for prior year ... from 2010 Company reaffirms 2011 guidance ...
Cached Medicine Technology:InterMune to Release Third Quarter Financial Results on November 3 2Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 2Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 3Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 4Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 5Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 6Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 7Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 8Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 9Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 10Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 11Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 12Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 13Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 14Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 15Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 16Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 17
(Date:4/18/2014)... discovery that turns 160 years of neuroanatomy on its ... to be essential for the fast transmission of impulses ... ubiquitous as thought, according to a new work lead ... Institute (HSCI) and the University,s Department of Stem Cell ... of Harvard,s Department of Molecular and Cellular Biology. , ...
(Date:4/18/2014)... 18, 2014) Benaroya Research Institute at Virginia Mason ... a particular molecule in metastatic breast cancer reduces both ... lung metastases. BRI scientists have found in models of ... by 60 - 80 percent and can keep the ... $1.8 million five-year grant comes from the National Cancer ...
(Date:4/18/2014)... is available in French . ... surgical practice and regenerative medicine. A team led by ... (CNRS/ESPCI Paris Tech) and Didier Letourneur from the Laboratoire ... has just demonstrated that the principle of adhesion by ... to repair soft-tissue organs and tissues. This easy-to-use gluing ...
(Date:4/17/2014)... inflammation in non-cancerous prostate tissue may have nearly twice ... with no inflammation, according to results of a new ... Cancer Center. , The link between persistent inflammation and ... prostate cancer those with a Gleason score between ... most aggressive and rapidly growing prostate cancers. , "What ...
(Date:4/17/2014)... most popular vaccine brands for children may not be ... some cost factors when choosing vaccines, driving the market ... to a new study by University of Illinois researchers. ... driven by numerous factors," says Sheldon H. Jacobson, a ... science and of mathematics at the U. of I. ...
Breaking Medicine News(10 mins):Health News:Finding turns neuroanatomy on its head 2Health News:Finding turns neuroanatomy on its head 3Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study recalculates costs of combination vaccines 2
... appears to be increasing among Veterans Affairs patients, although ... procedures// , according to a report. A second report ... other illnesses and reduced life expectancies may not necessarily ... but continue to be screened at high rates. ...
... comes in the way of the physical and mental growth ... the need to "protect, preserve and promote" the health of ... Health in the capital, Singh stressed: "Health is also a ... enjoy this right, it is even more important to respect ...
... ,UK scientists have developed a revolutionary vaccine for cancer that ... The vaccine is expected to be available within three years. ... leading to hopes that this could be the answer for ... cancer each year. ,In one patient who had ...
... influenza is causing pandemonium worldwide with more and more reports ... FDA has approved the labeling change after series of ... by people who had been taking this drug Unfortunately ... label approved by U.S FDA cautions medical practitioners to be ...
... the American Academy of Neurology and the Child Neurology Society ... a state of continuous seizures, in children, many of whom ... 2006, issue of Neurology, the scientific journal of the American ... term for a seizure, or series of seizures, that lasts ...
... published in the Lancet has brought to light that diabetes ... //community. With only 2.2percent of the Adult population of Indians ... the Indian body constitution is responsible. ,It is ... between the age groups of 30 and 50 has procured ...
Cached Medicine News:Health News:Studies Examine Colorectal Cancer Screening Rates 2Health News:Studies Examine Colorectal Cancer Screening Rates 3Health News:Studies Examine Colorectal Cancer Screening Rates 4Health News:PM Stress the Need to Protect Health of Children 2Health News:A Vaccine against Cancer 2Health News:Caution:Tamiflu ‘tames’ flu but psychiatric side effects now report 2Health News:New Guideline for the Diagnostic Assessment of Children with Continuous Seizures 2
Atkinson needles have a single bevel with a 22 angle point. Injecting anesthetic agents into the muscle cone. 0.60mm x 38.0mm (23 G x 1 1/2 in)...
Blunt, round tip facilitates easier separation of the nucleus. 45 6.0mm from tip, Blunt, Angled, 6.0mm from tip, 1.5mm from end...
... drape has two perforations which ... to various single or bilateral ... Refractive drape has two perforations ... adapts to various single or ...
Used after ablation to wash away particulate from anterior & posterior sides of flap & stromal bed. Conforms to the corneal flap. .0mm extension with a 11.0mm radius, Angled tip....
Medicine Products: